Skip to content

Comparison of the Efficacy of Two Different Suprascapular Nerve Block Techniques in Patients With Chronic Shoulder Pain

Comparison of Efficacy and Safety of Two Different Ultrasound-Guided Suprascapular Nerve Block Techniques in Chronic Shoulder Pain: A Prospective Double-Blinded Randomized Controlled Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04938037
Enrollment
80
Registered
2021-06-24
Start date
2021-06-01
Completion date
2022-08-05
Last updated
2025-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Shoulder Pain

Keywords

chronic shoulder pain, spinoglenoid notch, suprascapular nerve block, suprascapular notch

Brief summary

The aim of this study is to compare the efficacy and safety of the suprascapular nerve block (SSNB) at the spinoglenoid notch with SSNB at the suprascapular notch, which is the most commonly used technique in patients with chronic shoulder pain.

Detailed description

Chronic shoulder pain (\>3 months) is one of the most common musculoskeletal problems leading to psychosocial problems. Its causes include subacromial impingement, tendinosis, calcific tendinitis, complete or partial tendon tears, adhesive capsulitis, subacromial bursitis, glenohumeral osteoarthritis, glenohumeral instability, and acromioclavicular joint pathologies. For the treatment of chronic shoulder pain, conservative or surgical methods can be applied. Suprascapular nerve block (SSNB) is an effective and safe treatment option for pain relief and increases in functional activity in these patients. The suprascapular nerve (SSN) is a peripheral nerve has both motor and sensory fibers, originates from the ventral rami of C5-C6 nerve roots. SSN passes across the posterior triangle of the neck and through the suprascapular notch enters to the supraspinous fossa. Then it comes to the infraspinous fossa via the spinoglenoid notch. The SSN has 3 sensory branches: a medial subacromial branch passes to the suprascapular notch, a lateral subacromial branch and a posterior glenohumeral branch pass the spinoglenoid notch. These branches supplies 70% of the sensory input to the shoulder. In the literature, SSNB through suprascapular notch has positive effect on shoulder functions, pain and range of motion (ROM) in patients in the treatment of chronic shoulder pain. There is no study examining the efficacy of SSNB through spinoglenoid notch in the treatment of chronic shoulder pain.Therefore, the investigators planned this randomized trial to compare of the efficiency and safety of two different SSNB techniques (approach through suprascapular notch versus spinoglenoid notch) in treatment of patients with chronic shoulder pain. Material and methods: Participants: adult patients (\>18 year old) with chronic shoulder pain Inclusion criteria: age ≥ 18 years old, shoulder pain that last more than 3 month, patients with a vas value of ≥ 4 despite treatment (drugs used for analgesia, local injections and physiotherapy methods), shoulder pain defined as non-specific shoulder pain, subacromial impingement syndrome, rotator cuff tendinopathy, adhesive capsulitis, non-traumatic instability, superior labrum anterior and posterior (SLAP) lesion, acromioclavicular pathology, shoulder osteoarthritis. Exclusion criteria: A history of uncontrolled chronic diseases, e.g., malignant neoplasms, blood dyscrasia, previous surgery history at the affected shoulder, shoulder injection in the last 3 months before treatment, cervical radiculopathy or myelopathy, a previous fracture close to the shoulder region, septic arthritis or local infection in the affected shoulder, anaphylaxis against local anesthetics and/or corticosteroids, cardiac pacemaker, pregnancy. Study Design: prospective, double blind, non-inferiority, randomized controlled trial Randomization method: 1:1 by computer randomization program Detail of the intervention: Experimental: SSNB through the spinoglenoid notch US guided 1ml methylprednisolone acetate (1ml / 40mg) and 5ml 0.5% bupivacaine Intervention: Medication: corticosteroids and local anesthetics Active comparator: SSNB through the suprascapular notch US guided 1ml methylprednisolone acetate (1ml / 40mg) and 5ml 0.5% bupivacaine Intervention: Medication: corticosteroids and local anesthetics Outcome measurement: Visual analogue scale of pain, active range of motion, shoulder pain and disability index (SPADI), Pain Pressure Threshold (PPT), Patient satisfaction Statistical analyses: Sample size calculation: The sample size was calculated using http://statulator.com/SampleSize/ss2M.html considering a previous study. The non-inferiority margin for SPADI was taken as 9 points. Standard deviation 15.3 (assuming normal distribution) with a power of 80, an error of 0.05 type 1; 36 patients should be enrolled per groups. Including a rate of 10% drop-out 40 patients were planned to enroll in each groups. Continuous variables 1. Student's t test: fit assumption of normal distribution 2. Mann-Whitney test: does not fit the assumption of normal distribution Categorical variables 1\. Chi-square test 2. Fisher exact test: sparse data The outcome differences within the experimental and active comparator groups of different time of evaluation will be analysed by using repeated-measures analysis of variance (ANOVA) with post hoc test with Bonferroni method.

Interventions

PROCEDUREUS guided, SSNB with 1ml methylprednisolone acetate (1ml / 40mg) and 5 ml 0.5% bupivacaine

nerve block

Sponsors

TC Erciyes University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age ≥ 18 years old 2. Shoulder pain that last more than 3 month 3. Patients with a VAS value of ≥ 4 despite treatment (drugs used for analgesia, local injections and physiotherapy methods) 4. Shoulder pain defined as non-specific shoulder pain, subacromial impingement syndrome, rotator cuff tendinopathy, adhesive capsulitis, non-traumatic instability, SLAP lesion, acromioclavicular pathology, and / or shoulder osteoarthritis.

Exclusion criteria

1. A history of uncontrolled chronic diseases, e.g., malignant neoplasms, blood dyscrasia, and infection 2. Previous surgery history at the affected shoulder 3. Shoulder injection in the last 3 months before treatment 4. The presence of cervical radiculopathy or myelopathy 5. A previous fracture close to the shoulder region 6. Presence of septic arthritis or local infection in the affected shoulder 7. Presence of anaphylaxis against local anesthetics and / or corticosteroids 8. Presence of a cardiac pacemaker 9. Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Change of Shoulder Pain and Disability Index (SPADI)Baseline and 1, 4, and 12 weeks after injectionShoulder pain and disability index (SPADI). The SPADI contains 13 items that assess two domains; a 5-item subscale that measures pain and an 8-item subscale that measures disability. Each item is scored between 0 and 10, and the resulting score is converted into a 100-point scale separately for pain, disability, and total score. Increased SPADI scores indicate an increase in patients' shoulder-related pain and disability.

Secondary

MeasureTime frameDescription
Change of Visual Analog Scale (VAS)Baseline and 1, 4, and 12 weeks after injectionThe degree of shoulder pain for night and activity was assessed using Visual Analog Scale (VAS) (range 0-10) for each patient. VAS was explained to the patients during assessment as 0 equal no pain and 10 equal worst imaginable pain.
Change of Range of Motion (ROM)Baseline and 1, 4, and 12 weeks after injectionActive ROM of the affected shoulder is measured using a goniometer. These measurements included abduction, flexion, internal rotation, and external rotation.
Change of Pain Pressure Threshold (PPT)Baseline and 1, 4, and 12 weeks after injectionIn order to determine the pain perception thresholds in the affected shoulder, Pain Pressure Threshold (PPT) values will be calculated by taking three measurements from the middle deltoid, upper trapezius, infraspinatus and tibialis anterior area with an algometer (Commander Echo® Algometer, JTECH Medical, Midvale, UT, USA). The average of the last 2 measurements will be taken and recorded. The PPT values were expressed as kilograms per square centimeter (kg/cm2). A low PPT value represents a decrease in the pain threshold and, therefore, increased sensitivity.
Patient SatisfactionAssessed at baseline and 1, 4, and 12 weeks after injection, with week 12 reported.Patient satisfaction with the injection is determined by Likert Scale (1= very dissatisfied, 2= dissatisfied, 3=neither dissatisfied or satisfied, 4= satisfied, 5= very satisfied)

Countries

Turkey (Türkiye)

Participant flow

Participants by arm

ArmCount
SSNB Through the Spinoglenoid Notch
US guided 1ml methylprednisolone acetate (1ml / 40mg) and 5ml 0.5% bupivacaine Intervention: Medication: corticosteroids and local anesthetics US guided, SSNB with 1ml methylprednisolone acetate (1ml / 40mg) and 5 ml 0.5% bupivacaine: nerve block
40
SSNB Through the Suprascapular Notch
US guided 1ml methylprednisolone acetate (1ml / 40mg) and 5ml 0.5% bupivacaine Intervention: Medication: corticosteroids and local anesthetics US guided, SSNB with 1ml methylprednisolone acetate (1ml / 40mg) and 5 ml 0.5% bupivacaine: nerve block
40
Total80

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up43

Baseline characteristics

CharacteristicTotalSSNB Through the Suprascapular NotchSSNB Through the Spinoglenoid Notch
Affected shoulder, right50 Participants24 Participants26 Participants
Age, Continuous57.2 years
STANDARD_DEVIATION 8.7
57.2 years
STANDARD_DEVIATION 8.2
57.1 years
STANDARD_DEVIATION 9.3
BMI, kg/m229.6 Kg/m2
STANDARD_DEVIATION 5.3
30 Kg/m2
STANDARD_DEVIATION 5.1
29.2 Kg/m2
STANDARD_DEVIATION 5.6
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
80 Participants40 Participants40 Participants
Sex: Female, Male
Female
56 Participants27 Participants29 Participants
Sex: Female, Male
Male
24 Participants13 Participants11 Participants
Symptom duration, months14.9 months
STANDARD_DEVIATION 11
15.6 months
STANDARD_DEVIATION 12.3
14.2 months
STANDARD_DEVIATION 9.5

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 400 / 40
other
Total, other adverse events
4 / 404 / 40
serious
Total, serious adverse events
0 / 400 / 40

Outcome results

Primary

Change of Shoulder Pain and Disability Index (SPADI)

Shoulder pain and disability index (SPADI). The SPADI contains 13 items that assess two domains; a 5-item subscale that measures pain and an 8-item subscale that measures disability. Each item is scored between 0 and 10, and the resulting score is converted into a 100-point scale separately for pain, disability, and total score. Increased SPADI scores indicate an increase in patients' shoulder-related pain and disability.

Time frame: Baseline and 1, 4, and 12 weeks after injection

ArmMeasureGroupValue (MEAN)Dispersion
SSNB Through the Spinoglenoid NotchChange of Shoulder Pain and Disability Index (SPADI)SPADI- Total (Baseline- 4th week)27.0 score on a scaleStandard Deviation 22.2
SSNB Through the Spinoglenoid NotchChange of Shoulder Pain and Disability Index (SPADI)SPADI - Pain (Baseline - 12th week)30.3 score on a scaleStandard Deviation 26
SSNB Through the Spinoglenoid NotchChange of Shoulder Pain and Disability Index (SPADI)SPADI - Pain (Baseline - 1st week)25.9 score on a scaleStandard Deviation 22.2
SSNB Through the Spinoglenoid NotchChange of Shoulder Pain and Disability Index (SPADI)SPADI - Disability (Baseline - 1st week)20.3 score on a scaleStandard Deviation 20.3
SSNB Through the Spinoglenoid NotchChange of Shoulder Pain and Disability Index (SPADI)SPADI- Total (Baseline- 12th week)29.4 score on a scaleStandard Deviation 23
SSNB Through the Spinoglenoid NotchChange of Shoulder Pain and Disability Index (SPADI)SPADI - Disability (Baseline - 4th week)26.0 score on a scaleStandard Deviation 22.3
SSNB Through the Spinoglenoid NotchChange of Shoulder Pain and Disability Index (SPADI)SPADI - Pain (Baseline - 4th week)29.4 score on a scaleStandard Deviation 24.1
SSNB Through the Spinoglenoid NotchChange of Shoulder Pain and Disability Index (SPADI)SPADI - Disability (Baseline - 12th week)29.6 score on a scaleStandard Deviation 22.1
SSNB Through the Spinoglenoid NotchChange of Shoulder Pain and Disability Index (SPADI)SPADI- Total (Baseline- 1st week)22.1 score on a scaleStandard Deviation 20.3
SSNB Through the Suprascapular NotchChange of Shoulder Pain and Disability Index (SPADI)SPADI - Disability (Baseline - 12th week)33.0 score on a scaleStandard Deviation 29.2
SSNB Through the Suprascapular NotchChange of Shoulder Pain and Disability Index (SPADI)SPADI- Total (Baseline- 1st week)25.9 score on a scaleStandard Deviation 23.7
SSNB Through the Suprascapular NotchChange of Shoulder Pain and Disability Index (SPADI)SPADI- Total (Baseline- 4th week)36.6 score on a scaleStandard Deviation 22
SSNB Through the Suprascapular NotchChange of Shoulder Pain and Disability Index (SPADI)SPADI- Total (Baseline- 12th week)34.1 score on a scaleStandard Deviation 28.1
SSNB Through the Suprascapular NotchChange of Shoulder Pain and Disability Index (SPADI)SPADI - Pain (Baseline - 1st week)27.5 score on a scaleStandard Deviation 24.4
SSNB Through the Suprascapular NotchChange of Shoulder Pain and Disability Index (SPADI)SPADI - Pain (Baseline - 4th week)37.6 score on a scaleStandard Deviation 21.7
SSNB Through the Suprascapular NotchChange of Shoulder Pain and Disability Index (SPADI)SPADI - Pain (Baseline - 12th week)35.7 score on a scaleStandard Deviation 28.6
SSNB Through the Suprascapular NotchChange of Shoulder Pain and Disability Index (SPADI)SPADI - Disability (Baseline - 1st week)24.8 score on a scaleStandard Deviation 24.5
SSNB Through the Suprascapular NotchChange of Shoulder Pain and Disability Index (SPADI)SPADI - Disability (Baseline - 4th week)35.8 score on a scaleStandard Deviation 23.8
Secondary

Change of Pain Pressure Threshold (PPT)

In order to determine the pain perception thresholds in the affected shoulder, Pain Pressure Threshold (PPT) values will be calculated by taking three measurements from the middle deltoid, upper trapezius, infraspinatus and tibialis anterior area with an algometer (Commander Echo® Algometer, JTECH Medical, Midvale, UT, USA). The average of the last 2 measurements will be taken and recorded. The PPT values were expressed as kilograms per square centimeter (kg/cm2). A low PPT value represents a decrease in the pain threshold and, therefore, increased sensitivity.

Time frame: Baseline and 1, 4, and 12 weeks after injection

ArmMeasureGroupValue (MEAN)Dispersion
SSNB Through the Spinoglenoid NotchChange of Pain Pressure Threshold (PPT)PPT - upper trapezius (Baseline-1st week)-0.3 kg/cm2Standard Deviation 1.5
SSNB Through the Spinoglenoid NotchChange of Pain Pressure Threshold (PPT)PPT - upper trapezius (Baseline-4th week)-0.1 kg/cm2Standard Deviation 1.2
SSNB Through the Spinoglenoid NotchChange of Pain Pressure Threshold (PPT)PPT - upper trapezius (Baseline-12th week)-0.2 kg/cm2Standard Deviation 1.4
SSNB Through the Spinoglenoid NotchChange of Pain Pressure Threshold (PPT)PPT - middle deltoid (Baseline-1st week)-0.2 kg/cm2Standard Deviation 1
SSNB Through the Spinoglenoid NotchChange of Pain Pressure Threshold (PPT)PPT - middle deltoid (Baseline-4th week)0.0 kg/cm2Standard Deviation 1.5
SSNB Through the Spinoglenoid NotchChange of Pain Pressure Threshold (PPT)PPT - middle deltoid (Baseline-12th week)-0.2 kg/cm2Standard Deviation 1.6
SSNB Through the Spinoglenoid NotchChange of Pain Pressure Threshold (PPT)PPT - Infraspinatus (Baseline-1st week)-0.3 kg/cm2Standard Deviation 1.4
SSNB Through the Spinoglenoid NotchChange of Pain Pressure Threshold (PPT)PPT - Infraspinatus (Baseline-4th week)0.0 kg/cm2Standard Deviation 1.9
SSNB Through the Spinoglenoid NotchChange of Pain Pressure Threshold (PPT)PPT - Infraspinatus (Baseline-12th week)-0.4 kg/cm2Standard Deviation 1.7
SSNB Through the Spinoglenoid NotchChange of Pain Pressure Threshold (PPT)PPT - Tibialis Anterior (Baseline-1st week)-0.3 kg/cm2Standard Deviation 2.3
SSNB Through the Spinoglenoid NotchChange of Pain Pressure Threshold (PPT)PPT - Tibialis Anterior (Baseline-4th week)-0.1 kg/cm2Standard Deviation 1.9
SSNB Through the Spinoglenoid NotchChange of Pain Pressure Threshold (PPT)PPT - Tibialis Anterior (Baseline-12th week)-0.4 kg/cm2Standard Deviation 1.7
SSNB Through the Suprascapular NotchChange of Pain Pressure Threshold (PPT)PPT - Tibialis Anterior (Baseline-4th week)0.1 kg/cm2Standard Deviation 1.8
SSNB Through the Suprascapular NotchChange of Pain Pressure Threshold (PPT)PPT - upper trapezius (Baseline-1st week)0.0 kg/cm2Standard Deviation 1.5
SSNB Through the Suprascapular NotchChange of Pain Pressure Threshold (PPT)PPT - Infraspinatus (Baseline-1st week)-0.1 kg/cm2Standard Deviation 1.6
SSNB Through the Suprascapular NotchChange of Pain Pressure Threshold (PPT)PPT - upper trapezius (Baseline-4th week)-0.4 kg/cm2Standard Deviation 1.4
SSNB Through the Suprascapular NotchChange of Pain Pressure Threshold (PPT)PPT - Tibialis Anterior (Baseline-1st week)-0.2 kg/cm2Standard Deviation 1.4
SSNB Through the Suprascapular NotchChange of Pain Pressure Threshold (PPT)PPT - upper trapezius (Baseline-12th week)-0.3 kg/cm2Standard Deviation 1.3
SSNB Through the Suprascapular NotchChange of Pain Pressure Threshold (PPT)PPT - Infraspinatus (Baseline-4th week)-0.2 kg/cm2Standard Deviation 1.6
SSNB Through the Suprascapular NotchChange of Pain Pressure Threshold (PPT)PPT - middle deltoid (Baseline-1st week)0.3 kg/cm2Standard Deviation 1.5
SSNB Through the Suprascapular NotchChange of Pain Pressure Threshold (PPT)PPT - Tibialis Anterior (Baseline-12th week)-0.4 kg/cm2Standard Deviation 1.5
SSNB Through the Suprascapular NotchChange of Pain Pressure Threshold (PPT)PPT - middle deltoid (Baseline-4th week)0.1 kg/cm2Standard Deviation 1.8
SSNB Through the Suprascapular NotchChange of Pain Pressure Threshold (PPT)PPT - Infraspinatus (Baseline-12th week)-0.2 kg/cm2Standard Deviation 1.7
SSNB Through the Suprascapular NotchChange of Pain Pressure Threshold (PPT)PPT - middle deltoid (Baseline-12th week)-0.2 kg/cm2Standard Deviation 1.6
Secondary

Change of Range of Motion (ROM)

Active ROM of the affected shoulder is measured using a goniometer. These measurements included abduction, flexion, internal rotation, and external rotation.

Time frame: Baseline and 1, 4, and 12 weeks after injection

ArmMeasureGroupValue (MEAN)Dispersion
SSNB Through the Spinoglenoid NotchChange of Range of Motion (ROM)ROM flexion (Baseline- 1st week)-3.9 degreeStandard Deviation 16
SSNB Through the Spinoglenoid NotchChange of Range of Motion (ROM)ROM flexion (Baseline- 4th week)-8.6 degreeStandard Deviation 18.3
SSNB Through the Spinoglenoid NotchChange of Range of Motion (ROM)ROM flexion (Baseline- 12th week)-8.8 degreeStandard Deviation 18.1
SSNB Through the Spinoglenoid NotchChange of Range of Motion (ROM)ROM abduction (Baseline- 1st week)-4.8 degreeStandard Deviation 14.4
SSNB Through the Spinoglenoid NotchChange of Range of Motion (ROM)ROM abduction (Baseline- 4th week)-14.1 degreeStandard Deviation 24.9
SSNB Through the Spinoglenoid NotchChange of Range of Motion (ROM)ROM abduction (Baseline- 12th week)-13.0 degreeStandard Deviation 27.7
SSNB Through the Spinoglenoid NotchChange of Range of Motion (ROM)ROM internal rotation (Baseline- 1st week)0.9 degreeStandard Deviation 4.7
SSNB Through the Spinoglenoid NotchChange of Range of Motion (ROM)ROM internal rotation (Baseline- 4th week)-0.9 degreeStandard Deviation 3.2
SSNB Through the Spinoglenoid NotchChange of Range of Motion (ROM)ROM internal rotation (Baseline- 12th week)-2.4 degreeStandard Deviation 7
SSNB Through the Spinoglenoid NotchChange of Range of Motion (ROM)ROM external rotation (Baseline- 1st week)-2.5 degreeStandard Deviation 6.9
SSNB Through the Spinoglenoid NotchChange of Range of Motion (ROM)ROM external rotation (Baseline- 4th week)-6.0 degreeStandard Deviation 8.9
SSNB Through the Spinoglenoid NotchChange of Range of Motion (ROM)ROM external rotation (Baseline- 12th week)-8.5 degreeStandard Deviation 12.3
SSNB Through the Suprascapular NotchChange of Range of Motion (ROM)ROM external rotation (Baseline- 4th week)-10.9 degreeStandard Deviation 16
SSNB Through the Suprascapular NotchChange of Range of Motion (ROM)ROM flexion (Baseline- 1st week)-9.6 degreeStandard Deviation 14
SSNB Through the Suprascapular NotchChange of Range of Motion (ROM)ROM internal rotation (Baseline- 1st week)-4.5 degreeStandard Deviation 9.7
SSNB Through the Suprascapular NotchChange of Range of Motion (ROM)ROM flexion (Baseline- 4th week)-18.6 degreeStandard Deviation 21.2
SSNB Through the Suprascapular NotchChange of Range of Motion (ROM)ROM external rotation (Baseline- 1st week)-6.8 degreeStandard Deviation 17.3
SSNB Through the Suprascapular NotchChange of Range of Motion (ROM)ROM flexion (Baseline- 12th week)-20.5 degreeStandard Deviation 22.2
SSNB Through the Suprascapular NotchChange of Range of Motion (ROM)ROM internal rotation (Baseline- 4th week)-7.5 degreeStandard Deviation 11.9
SSNB Through the Suprascapular NotchChange of Range of Motion (ROM)ROM abduction (Baseline- 1st week)-9.6 degreeStandard Deviation 16.1
SSNB Through the Suprascapular NotchChange of Range of Motion (ROM)ROM external rotation (Baseline- 12th week)-10.0 degreeStandard Deviation 20.3
SSNB Through the Suprascapular NotchChange of Range of Motion (ROM)ROM abduction (Baseline- 4th week)-23.9 degreeStandard Deviation 30.1
SSNB Through the Suprascapular NotchChange of Range of Motion (ROM)ROM internal rotation (Baseline- 12th week)-8.6 degreeStandard Deviation 12.2
SSNB Through the Suprascapular NotchChange of Range of Motion (ROM)ROM abduction (Baseline- 12th week)-26.0 degreeStandard Deviation 29.1
Secondary

Change of Visual Analog Scale (VAS)

The degree of shoulder pain for night and activity was assessed using Visual Analog Scale (VAS) (range 0-10) for each patient. VAS was explained to the patients during assessment as 0 equal no pain and 10 equal worst imaginable pain.

Time frame: Baseline and 1, 4, and 12 weeks after injection

ArmMeasureGroupValue (MEAN)Dispersion
SSNB Through the Spinoglenoid NotchChange of Visual Analog Scale (VAS)VAS Activity (Baseline - 1st week)2.2 score on a scaleStandard Deviation 2.5
SSNB Through the Spinoglenoid NotchChange of Visual Analog Scale (VAS)VAS Activity (Baseline - 4st week)2.8 score on a scaleStandard Deviation 2.7
SSNB Through the Spinoglenoid NotchChange of Visual Analog Scale (VAS)VAS Activity (Baseline - 12th week)2.9 score on a scaleStandard Deviation 2.7
SSNB Through the Spinoglenoid NotchChange of Visual Analog Scale (VAS)VAS Night (Baseline - 1st week)3.2 score on a scaleStandard Deviation 2.6
SSNB Through the Spinoglenoid NotchChange of Visual Analog Scale (VAS)VAS Night (Baseline - 4st week)3.4 score on a scaleStandard Deviation 2.6
SSNB Through the Spinoglenoid NotchChange of Visual Analog Scale (VAS)VAS Night (Baseline - 12th week)3.1 score on a scaleStandard Deviation 2.7
SSNB Through the Suprascapular NotchChange of Visual Analog Scale (VAS)VAS Night (Baseline - 4st week)3.9 score on a scaleStandard Deviation 2.4
SSNB Through the Suprascapular NotchChange of Visual Analog Scale (VAS)VAS Activity (Baseline - 1st week)2.8 score on a scaleStandard Deviation 2.5
SSNB Through the Suprascapular NotchChange of Visual Analog Scale (VAS)VAS Night (Baseline - 1st week)3.0 score on a scaleStandard Deviation 2.9
SSNB Through the Suprascapular NotchChange of Visual Analog Scale (VAS)VAS Activity (Baseline - 4st week)3.7 score on a scaleStandard Deviation 2.4
SSNB Through the Suprascapular NotchChange of Visual Analog Scale (VAS)VAS Night (Baseline - 12th week)3.3 score on a scaleStandard Deviation 3.2
SSNB Through the Suprascapular NotchChange of Visual Analog Scale (VAS)VAS Activity (Baseline - 12th week)3.5 score on a scaleStandard Deviation 2.9
Secondary

Patient Satisfaction

Patient satisfaction with the injection is determined by Likert Scale (1= very dissatisfied, 2= dissatisfied, 3=neither dissatisfied or satisfied, 4= satisfied, 5= very satisfied)

Time frame: Assessed at baseline and 1, 4, and 12 weeks after injection, with week 12 reported.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
SSNB Through the Spinoglenoid NotchPatient SatisfactionDissatisfied8 Participants
SSNB Through the Spinoglenoid NotchPatient SatisfactionSatisfied12 Participants
SSNB Through the Spinoglenoid NotchPatient Satisfactionneither dissatisfied or satisfied3 Participants
SSNB Through the Spinoglenoid NotchPatient SatisfactionExtremely satisfied14 Participants
SSNB Through the Spinoglenoid NotchPatient SatisfactionExtremely dissatisfied3 Participants
SSNB Through the Suprascapular NotchPatient SatisfactionExtremely satisfied20 Participants
SSNB Through the Suprascapular NotchPatient SatisfactionExtremely dissatisfied2 Participants
SSNB Through the Suprascapular NotchPatient SatisfactionDissatisfied1 Participants
SSNB Through the Suprascapular NotchPatient Satisfactionneither dissatisfied or satisfied6 Participants
SSNB Through the Suprascapular NotchPatient SatisfactionSatisfied11 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026